Net Loss Per Share

3 Months Ended

Mar. 31, 2024

As discussed in Note 7, on March 6, 2023, in connection with the 15th amendment to our Credit Agreement, the Company issued a warrant to purchase up to 80,000 shares of the Company common stock at an exercise price of $0.25 per share, which vested on September 6, 2023. On December 5, 2023, we issued a warrant to purchase an additional 80,000 shares of our common stock at an exercise price of $0.25 per share which are vested. The warrants are considered exercisable for 160,000 shares for little to no consideration and the shares are therefore included in basic shares outstanding at their issuance date.

The Company’s potentially dilutive securities, which include unvested RSUs, stock options to purchase common stock and warrants to purchase common stock, have been excluded from the computation of diluted net loss per share for certain periods, as the effect would be antidilutive. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same in periods of a net loss. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share

for the periods indicated because including them would have had an anti-dilutive effect (adjusted for after the Reverse Stock Split):


	Three Months Ended March 31,
	2024	2023
Public warrants	500,000	500,000
Private warrants	13,300	13,300
Stock options	336,270	336,563
Unvested restricted stock units	222,800	193,896
Warrants issued in connection with 15th amendment to Credit Agreement	—	80,000
Total common stock equivalents	1,072,370	1,123,759